WHO ICTRP trial
Empagliflozin effect on supraventricular arrhythmias
IRCT20240116060704N1 · Iranian Registry of Clinical Trials (IRCT) · Recruiting
Key facts
| Trial ID | IRCT20240116060704N1 |
|---|---|
| Public title | Empagliflozin effect on supraventricular arrhythmias |
| Scientific title | Empagliflozin effect on supraventricular arrhythmias in heart failure patients with implantable cardioverter-defibrillator |
| Primary sponsor | Bagheiat-allah University of Medical Sciences |
| Secondary sponsors | Mashhad University of Medical Sciences |
| Registry | Iranian Registry of Clinical Trials (IRCT) |
| Recruitment status | Recruiting |
| Study type | interventional |
| Phase | 3 |
| Countries | Iran (Islamic Republic of);Iran (Islamic Republic of) |
| Conditions | Supraventricular arrhythmias. Atrial fibrillation and flutter |
| Interventions | Intervention group: Taking empagliflozin tablets from Abidi Company, 10 mg/day in the morning, regardless of food for three months (30 patients). |
| Registration date | Jan 22, 2024 |
| Target size | 30 |
| Registry page | irct.behdasht.gov.ir |
At a glance
- No Results available
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About WHO ICTRP trial registrations
The WHO ICTRP combines trial registrations from primary registries worldwide into a single searchable index. Contact and ethics-committee details are not shown here.
Source: World Health Organization (WHO), International Clinical Trials Registry Platform (ICTRP) · Source date: